



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

86738 7590 11/08/2017
MCCARTER & ENGLISH, LLP BOSTON
265 Franklin Street
Boston, MA 02110

EXAMINER

AULAKH, CHARANJIT

ART UNIT

PAPER NUMBER

1625

DATE MAILED: 11/08/2017

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

15/591,605

05/10/2017

Giles Albert Brown

125345-00702

5816

TITLE OF INVENTION: BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
-------------	---------------	---------------	---------------------	----------------------	------------------	----------

nonprovisional

UNDISCOUNTED

\$960

\$0

\$0

\$960

02/08/2018

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Maintenance fees are due in utility patents issuing on applications filed on or after Dec. 12, 1980. It is patentee's responsibility to ensure timely payment of maintenance fees when due. More information is available at www.uspto.gov/PatentMaintenanceFees.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: **Mail** **Mail Stop ISSUE FEE**
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax **(571)-273-2885**

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

86738 7590 11/08/2017
MCCARTER & ENGLISH, LLP BOSTON
 265 Franklin Street
 Boston, MA 02110

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/591,605	05/10/2017	Giles Albert Brown	125345-00702	5816

TITLE OF INVENTION: BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$960	\$0	\$0	\$960	02/08/2018

EXAMINER	ART UNIT	CLASS-SUBCLASS
AULAKH, CHARANJIT	1625	514-278000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. ☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.	2. For printing on the patent front page, list (1) The names of up to 3 registered patent attorneys or agents OR, alternatively, 1 _____ (2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. 2 _____ 3 _____
---	---

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ☐ Individual ☐ Corporation or other private group entity ☐ Government

4a. The following fee(s) are submitted:

- ☐ Issue Fee
☐ Publication Fee (No small entity discount permitted)
☐ Advance Order - # of Copies _____

4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)

- ☐ A check is enclosed.
☐ Payment by credit card. Form PTO-2038 is attached.
☐ The director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

- ☐ Applicant certifying micro entity status. See 37 CFR 1.29
☐ Applicant asserting small entity status. See 37 CFR 1.27
☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____ Date _____
 Typed or printed name _____ Registration No. _____



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/591,605	05/10/2017	Giles Albert Brown	125345-00702	5816

86738 7590 11/08/2017
MCCARTER & ENGLISH, LLP BOSTON
265 Franklin Street
Boston, MA 02110

EXAMINER

AULAKH, CHARANJIT

ART UNIT	PAPER NUMBER
----------	--------------

1625

DATE MAILED: 11/08/2017

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Notice of Allowability	Application No. 15/591,605	Applicant(s) BROWN ET AL.	
	Examiner Charanjit Aulakh	Art Unit 1625	AIA (First Inventor to File) Status Yes

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to Paper filed on 11 October 2017.
☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.
2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.
3. ☒ The allowed claim(s) is/are 27-44. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

- a) ☐ All b) ☐ Some *c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|---|---|
| 1. ☐ Notice of References Cited (PTO-892) | 5. ☒ Examiner's Amendment/Comment |
| 2. ☒ Information Disclosure Statements (PTO/SB/08),
Paper No./Mail Date <u>7/12/17, 10/11/17</u> | 6. ☐ Examiner's Statement of Reasons for Allowance |
| 3. ☐ Examiner's Comment Regarding Requirement for Deposit
of Biological Material | 7. ☐ Other _____. |
| 4. ☐ Interview Summary (PTO-413),
Paper No./Mail Date _____. | |

/Charanjit Aulakh/
Primary Examiner, Art Unit 1625

DETAILED ACTION

1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA.
2. In a preliminary amendment filed on July 12, 2017, the applicants have added new claims 36-44.
3. According to paper filed on Oct. 11, 2017, the applicants have amended claims 28 and 29.
4. Claims 27-44 are now pending in the application.
5. Claims 27-44, renumbered as claims 1-18, are allowed since the applicants have amended claims to overcome indefiniteness rejection and furthermore, have filed a terminal disclaimer to overcome ODP rejection.
6. The drawings are accepted.
7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charanjit Aulakh whose telephone number is (571)272-0678. The examiner can normally be reached on Monday through Friday, 8:30 A.M. to 5:00 P.M..

Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at <http://www.uspto.gov/interviewpractice>.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Kosar can be reached on (571)272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Charanjit Aulakh/
Primary Examiner, Art Unit 1625

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		15591605
	Filing Date		2017-05-10
	First Named Inventor	Giles Albert Brown	
	Art Unit	N/A	
	Examiner Name	Not Yet Assigned	
	Attorney Docket Number	125345-00702	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	9670183		2017-06-06	Brown et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2009/034380	WO	A1	2009-03-19	Astrazeneca Ab		
	2	2007100664	WO	A2	2007-09-07	Vertex Pharmaceuticals Inc		
	3	2010049146	WO	A1	2010-05-06	Gruenenthal GMBH		

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15591605
Filing Date	2017-05-10
First Named Inventor	Giles Albert Brown
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	125345-00702

4	2010130945	WO	A1	2010-11-18	Sanofi Aventis	
---	------------	----	----	------------	----------------	--

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1		

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/CHARANJIT AULAKH/	Date Considered	10/24/2017
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15591605
Filing Date	2017-05-10
First Named Inventor	Giles Albert Brown
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	125345-00702

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Mei Bai/	Date (YYYY-MM-DD)	2017-07-12
Name/Print	Mei Bai, Ph.D.	Registration Number	64,507

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	15591605
	Filing Date	2017-05-10
	First Named Inventor	Giles Albert Brown
	Art Unit	1625
	Examiner Name	C. Aulakh
	Attorney Docket Number	125345-00702

U.S.PATENTS							Remove
--------------------	--	--	--	--	--	--	------------------------

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)

U.S.PATENT APPLICATION PUBLICATIONS							Remove
--	--	--	--	--	--	--	------------------------

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)

FOREIGN PATENT DOCUMENTS								Remove
---------------------------------	--	--	--	--	--	--	--	------------------------

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							

If you wish to add additional Foreign Patent Document citation information please click the Add button

[Add](#)

NON-PATENT LITERATURE DOCUMENTS							Remove
--	--	--	--	--	--	--	------------------------

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15591605
Filing Date	2017-05-10
First Named Inventor	Giles Albert Brown
Art Unit	1625
Examiner Name	C. Aulakh
Attorney Docket Number	125345-00702

/C.A/	1	Search Report GB1416622.7, mailed June 3, 2015.
/C.A/	2	Search Report GB1402013.5, mailed August 27, 2014

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/CHARANJIT AULAKH/	Date Considered	10/24/2017
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15591605
Filing Date	2017-05-10
First Named Inventor	Giles Albert Brown
Art Unit	1625
Examiner Name	C. Aulakh
Attorney Docket Number	125345-00702

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.

- ☒ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Mei Bai/	Date (YYYY-MM-DD)	2017-10-11
Name/Print	Mei Bai, Ph.D.	Registration Number	64,507

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement


The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:


1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

REIVINDICACIONES MODIFICADAS SOLICITUD DE PATENTE Núm.
NC2016/0001609- DICIEMBRE 2017


1. Un compuesto de la fórmula (1b):




o una sal de este, en donde el resto




se selecciona de los grupos AAA a ACB, BAA a BCZ, CAA a CBZ, DAA a DBG y EAA a EAB:




AAA




AAB




AAC




AAD




AAE




AAF




AAG




AAH




AAI




AAJ




AAK




AAL




AAM




AAN




AAO




AAP




AAQ




AAR




AAS




AAT




AAU




AAV




AAW




AAX




AAY




AAZ




ABA




ABB




ABC




ABD




ABE




ABF




ABG




ABH




ABI




ABJ




ABK




ABL




ABM




ABN




ABO




ABP




ABQ




ABR




ABS




ABT




ABU




ABV




ABW




ABX




ABY




ABZ




ACA




ACB




BAA




BAB




BAC




BAD




BAE




BAF




BAG




BAH




BAI




BAJ




BAK




BAL




BAM




BAN




BAO




BAP




BAQ




BAR




BAS




BAT




BAU




BAV




BAW




BAX




BAY




BAZ




BBA




BBB




BBC




BBD




BBE




BBF




BBG




BBH




BBI




BBJ




BBK




BBL




BBM




BBN




BBO




BBP




BBQ




BBR




BBS




BBT




BBU




BBV




BBW




BBX




BBY




BBZ




BCA




BCB




BCD




BCE




BCF




BCG




BCH




BCI




BCJ




BCK




BCL




BCM




BCN




BCO




BCP




BCQ




BCR




BCS




BCT




BCU




BCV




BCW




BCX




BCY




BCZ




CAA




CAB




CAC




CAD




CAE




CAF




CAG




CAH




CAI




CAJ




CAK




CAL




CAM




CAN




CAO




CAP




CAQ




CAR




CAS




CAT




CAU




CAV




CAW




CAX




CAY




CAZ




CBA




CBB




CBC




CBD




CBE




CBF




CBG




CBH




CBI




CBJ




CBK




CBL




CBM




CBN




CBO




CBP




CBQ




CBR




CBS




CBT




CBU




CBV




CBW




CBX




CBY




CBZ




DAA




DAB




DAC




DAD




DAE




DAF




DAG




DAH




DAI




DAJ




DAK




DAL




DAM




DAN




DAO




DAP




DAQ




DAR




DAS




DAT




DAU




DAV




DAW




DAX




DAY




DAZ




DBA




DBB




DBC




DBD




DBE




DBF



DBG



EAA



EAB

y R^4 es un hidrógeno o un grupo hidrocarburo no aromático C_{1-6} que está sustituido o no sustituido con uno a seis átomos de flúor.

2. Un compuesto de acuerdo con la reivindicación 1 donde R^4 se selecciona de hidrógeno y metilo.

3. Un compuesto de acuerdo con la reivindicación 1 donde la sal es una sal farmacéuticamente aceptable.

4. Un compuesto de acuerdo con la reivindicación 1 que se selecciona de:

2-[4-(1-metil-1H-pirazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1H-pirrol-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1H-pirazol-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1-etil-1H-pirazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(2H-1,2,3-triazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-propanoilpirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[1-(metilcarbamoil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(metoxicarbonil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-4,4-difluoro-2-(metoxicarbonil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-4,4-difluoro-2-(1-hidroxietil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-2-metil-5-oxopirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-2-etil-5-oxopirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-2-metil-5-oxopirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(2,2-dimetil-5-oxopirrolidin-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R,4S)-4-fluoro-2-(metoxicarbonil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R,4R)-4-fluoro-2-(hidroximetil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-ciano-4-(piridin-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-(2-oxo-3,4'-bipiperidin-1'-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[2-(metoxicarbonil)azepan-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo.

5. Un compuesto de acuerdo con la reivindicación 1, que se selecciona de:

2-[4-(1H-imidazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(4-cloro-1H-imidazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[4-(trifluorometil)-1H-imidazol-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(4-ciano-1H-imidazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(4,5-dicloro-1H-imidazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1-metil-1H-imidazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de metilo

2-[4-(1-metil-1H-imidazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[1-(etoxicarbonil)-1H-imidazol-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1,5-dimetil-1H-imidazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de metilo

2-[4-(1,5-dimetil-1H-imidazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1,4-dimetil-1H-imidazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de metilo

2-[4-(1,4-dimetil-1H-imidazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(5-cloro-1-metil-1H-imidazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de metilo

2-[4-(5-cloro-1-metil-1H-imidazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-[1-metil-4-(trifluorometil)-1H-imidazol-2-il]piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(4,5-dicloro-1-metil-1H-imidazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de metilo

2-[4-(4,5-dicloro-1-metil-1H-imidazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1H-pirazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(3-amino-1H-pirazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1-metil-1H-pirazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de metilo

2-[4-(1-metil-1H-pirazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1-metil-1H-pirazol-3-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1,3-oxazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1,3-tiazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de metilo

2-[4-(1,3-tiazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(4H-1,2,4-triazol-3-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(5-etil-1H-1,2,4-triazol-3-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato

de etilo

2-[4-(1,3,4-oxadiazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(3-metil-1,2,4-oxadiazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1,2,4-tiadiazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1H-tetrazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1H-pirrol-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1H-pirazol-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(4-metil-1H-pirazol-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1H-1,2,3-triazol-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1H-1,2,4-triazol-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-hidroxi-4-(1H-imidazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1H-imidazol-2-il)-4-metoxipiperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-hidroxi-4-(1-metil-1H-imidazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-metoxi-4-(1-metil-1H-imidazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-metil-4-(3-metil-1,2,4-oxadiazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(4-metil-1H-pirazol-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de metilo

2-[4-(1,2-oxazol-3-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(3-metil-1H-pirazol-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(3-metil-1H-pirazol-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de

metilo

2-[4-(1-etil-1H-pirazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de metilo

2-[4-(1-etil-1H-pirazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1-propil-1H-pirazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de metilo

2-[4-(1-propil-1H-pirazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1,3-tiazol-4-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-[1-(2-metoxietil)-1H-imidazol-2-il]piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-[1-(cianometil)-1H-imidazol-2-il]piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

Ácido (2-{1-[6-(etoxicarbonil)-6-azaspiro[3.4]oct-2-il]piperidin-4-il}-1H-imidazol-1-il)acético

2-(4-{1-[2-(metilamino)-2-oxoetil]-1H-imidazol-2-il}piperidin-1-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1,4-dimetil-1H-pirazol-3-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de metilo

2-[4-(1,4-dimetil-1H-pirazol-3-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1,4-dimetil-1H-pirazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de metilo

2-[4-(1,4-dimetil-1H-pirazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1-etil-4-metil-1H-pirazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(4-etil-1-metil-1H-pirazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(2H-1,2,3-triazol-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de

etilo

2-[4-(1H-tetrazol-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(5-metil-1H-tetrazol-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1-metil-1H-tetrazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1-etil-1H-tetrazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(2-etil-2H-tetrazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1-ciclopropil-1H-tetrazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1H-pirazol-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de (1,1-²H₂)etilo

2-[4-(1H-pirazol-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de (2,2,2-²H₃)etilo

2-[4-(1H-pirazol-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de (²H₅)etilo

2-[4-(1-metil-1H-pirazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de (1,1-²H₂)etilo

2-[4-(1-metil-1H-pirazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de (2,2,2-²H₃)etilo

2-[4-(1-metil-1H-pirazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de (²H₅)etilo

2-[4-(pirrolidin-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1-formilpirrolidin-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1-acetilpirrolidin-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-[1-(trifluoroacetil)pirrolidin-2-il]piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1-propanoilpirrolidin-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de metilo

2-[4-(1-propanoilpirrolidin-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-propanoilpirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(ciclopropilcarbonil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(ciclobutilcarbonil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[1-(metoxicarbonil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de metilo

2-{4-[1-(metoxicarbonil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(metoxicarbonil)pirrolidin-2-il]pirrolidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-1-(metoxicarbonil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[1-(etoxicarbonil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(metilcarbamoil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de metilo

2-{4-[1-(metilcarbamoil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(metilcarbamoil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-1-(metilcarbamoil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[1-(etilcarbamoil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[1-(dimetilcarbamoil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-

carboxilato de etilo

2-{4-[(2S)-1-(dimetilcarbamoil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(1-metilpirrolidin-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[1-(N-metilglicil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[1-(metoxicarbamoil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(propan-2-ilcarbamoil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-(4-{(2S)-1-[(2,2,2-trifluoroetil)carbamoil]pirrolidin-2-il}piperidin-1-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(azetidin-1-ilcarbonil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(morfolin-4-ilcarbonil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(ciclopropilcarbamoil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(ciclobutilcarbamoil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-(4-{(2S)-1-[(2-metoxietil)carbamoil]pirrolidin-2-il}piperidin-1-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(pirrolidin-1-ilcarbonil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(metoxicarbamoil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-(4-{(2S)-1-[(metoxi(metil)carbamoil]pirrolidin-2-il}piperidin-1-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-(4-{(2S)-1-[(1-metilciclobutil)carbamoil]pirrolidin-2-il}piperidin-1-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-(4-{(2S)-1-[(3-metiloxetan-3-il)carbamoil]pirrolidin-2-il}piperidin-1-il)-6-
 azaspiro[3.4]octano-6-carboxilato de etilo

2-(4-{(2S)-1-[(3,3-difluoropirrolidin-1-il)carbonil]pirrolidin-2-il}piperidin-1-il)-6-
 azaspiro[3.4]octano-6-carboxilato de etilo

2-(4-{(2S)-1-[(3,3-difluorociclobutil)carbamoil]pirrolidin-2-il}piperidin-1-il)-6-
 azaspiro[3.4]octano-6-carboxilato de etilo

2-(4-{(2S)-1-[(3,3-difluoroazetidin-1-il)carbonil]pirrolidin-2-il}piperidin-1-il)-6-
 azaspiro[3.4]octano-6-carboxilato de etilo

2-(4-{(2S)-1-[(2,2,2-trifluoroetil)carbamoil]pirrolidin-2-il}piperidin-1-il)-6-
 azaspiro[3.4]octano-6-carboxilato de metilo

2-(4-{(2S)-1-[(3,3-difluoroazetidin-1-il)carbonil]pirrolidin-2-il}piperidin-1-il)-6-
 azaspiro[3.4]octano-6-carboxilato de metilo

2-(4-{(2S)-1-[(etil(propan-2-il)carbamoil]pirrolidin-2-il}piperidin-1-il)-6-
 azaspiro[3.4]octano-6-carboxilato de etilo

2-(4-{(2S)-1-[(ciclobutiloxi)carbonil]pirrolidin-2-il}piperidin-1-il)-6-
 azaspiro[3.4]octano-6-carboxilato de etilo

2-(4-{(2S)-1-[(2-fluoroetil)carbamoil]pirrolidin-2-il}piperidin-1-il)-6-
 azaspiro[3.4]octano-6-carboxilato de etilo

2-(4-{(2S)-1-[(2,2-difluoroetil)carbamoil]pirrolidin-2-il}piperidin-1-il)-6-
 azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(metoxiacetil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-
 carboxilato de etilo

2-(4-{(2S)-1-[(2-fluoroetoxi)carbonil]pirrolidin-2-il}piperidin-1-il)-6-
 azaspiro[3.4]octano-6-carboxilato de etilo

2-(4-{(2S)-1-[(2,2,2-trifluoroetoxi)carbonil]pirrolidin-2-il}piperidin-1-il)-6-
 azaspiro[3.4]octano-6-carboxilato de etilo

2-(4-{(2S)-1-[(metilsulfanil)carbonil]pirrolidin-2-il}piperidin-1-il)-6-
 azaspiro[3.4]octano-6-carboxilato de etilo

2-(4-{(2S)-1-[(2-metoxietoxi)carbonil]pirrolidin-2-il}piperidin-1-il)-6-
 azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-[[2-(dimetilamino)etoxi]carbonil]pirrolidin-2-il]piperidin-1-il}-6-

azaspiro[3.4]octano-6-carboxilato de etilo
 2-{4-[(2S)-1-(hidroxiacetil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo
 2-{4-[(2S)-1-(3,3,3-trifluoropropanoil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo
 2-(4-{(2S)-1-[(piridin-2-ilmetil)carbamoil]pirrolidin-2-il}piperidin-1-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo
 2-(4-{(2S)-1-[metil(2,2,2-trifluoroetil)carbamoil]pirrolidin-2-il}piperidin-1-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo
 2-{4-[(2S)-1-(oxetan-3-ilcarbamoil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo
 2-(4-{(2S)-1-[(metil(oxetan-3-il)carbamoil]pirrolidin-2-il}piperidin-1-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo
 2-{4-[(2S)-1-propanotioilpirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo
 2-{4-[(2S,4S)-4-fluoro-1-propanoilpirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo
 2-{4-[(2S)-4,4-difluoro-1-propanoilpirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo
 2-{4-[(2S)-1-etilpirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo
 2-(4-{(2S)-1-[3-(piridin-2-il)propanoil]pirrolidin-2-il}piperidin-1-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo
 2-(4-{(2S)-1-[metil(piridin-2-ilmetil)carbamoil]pirrolidin-2-il}piperidin-1-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo
 2-(4-{(2S)-1-[(piridin-2-ilmetoxi)carbonil]pirrolidin-2-il}piperidin-1-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo
 2-{4-[(2S)-1-{N-[(benciloxi)carbonil]- β -alanil}pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo
 2-{4-[(2S)-1-(β -alanil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-{[2-(metilamino)etoxi]carbonil}pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(2-fluoroetil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(2,2,2-trifluoroetil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(3,3,3-trifluoropropil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(2-metoxietil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(2-metoxi-2-oxoetil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-[2-(dimetilamino)-2-oxoetil]pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-bencilpirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(metilcarbamoil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[2-(metilcarbamoil)-2,3-dihidro-1H-isoindol-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-fenilpirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(piridin-2-il)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de metilo

2-{4-[(2S)-1-(piridin-2-il)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(piridin-4-il)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(pirimidin-2-il)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(1,3-tiazol-2-il)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-

carboxilato de etilo

2-{4-[(2S)-1-(1,3,4-tiadiazol-2-il)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-2-(metoxycarbonil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-2-(metilcarbamoil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

1-{1-[6-(etoxycarbonil)-6-azaspiro[3.4]oct-2-il]piperidin-4-il}-4,4-difluoro-D-prolina

2-{4-[(2R)-4,4-difluoro-2-(metoxycarbonil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-4,4-difluoro-2-(metilcarbamoil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-2-(dimetilcarbamoil)-4,4-difluoropirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-2-carbamoil-4,4-difluoropirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-4,4-difluoro-2-(metoxycarbamoil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-4,4-difluoro-2-[metoxi(metil)carbamoil]pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-4,4-difluoro-2-(metilcarbamoil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-2-(dimetilcarbamoil)-4,4-difluoropirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-2-(metoxycarbonil)-2-metilpirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(6-oxo-7-oxa-1-azaspiro[4.4]non-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(4S)-4-(metoxycarbonil)-1,3-tiazolidin-3-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(3R)-3-fluoropirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato

de etilo

2-{4-[(3S)-3-fluoropirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(3,3-difluoropirrolidin-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-2-(trifluorometil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-2-(fluorometil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-2-(difluorometil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-2-(trifluorometil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(3-azabicyclo[3.1.0]hex-3-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-4,4-difluoro-2-metilpirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-4,4-difluoro-2-(hidroximetil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-4,4-difluoro-2-(metoximetil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-4,4-difluoro-2-(1-hidroxietil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-4,4-difluoro-2-(1-hidroxietil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-4,4-difluoro-2-(2-hidroxiopropan-2-il)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(2-oxopirrolidin-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(2,5-dioxopirrolidin-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-2-metil-5-oxopirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-

carboxilato de etilo

2-{4-[(2R)-2-etil-5-oxopirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-2-metil-5-oxopirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-2-etil-5-oxopirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(2,2-dimetil-5-oxopirrolidin-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(4R)-4-metil-2-oxo-1,3-oxazolidin-3-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(4R)-4-etil-2-oxo-1,3-oxazolidin-3-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(4R)-2-oxo-4-(propan-2-il)-1,3-oxazolidin-3-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(4S)-4-metil-2-oxo-1,3-oxazolidin-3-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(4S)-4-etil-2-oxo-1,3-oxazolidin-3-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(4S)-2-oxo-4-(propan-2-il)-1,3-oxazolidin-3-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(2-oxoimidazolidin-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato

2-[4-(3-metil-2-oxoimidazolidin-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[2-(1H-pirazol-5-il)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[2-(1,2-oxazol-3-il)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[2-(1H-tetrazol-5-il)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[2-(2-metil-2H-tetrazol-5-il)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-

6-carboxilato de etilo

2-{4-[2-(1-metil-1H-tetrazol-5-il)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-2-(tiofen-2-il)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R)-2-(1,3-tiazol-2-il)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(5,7-dihidro-6H-pirrol[3,4-b]piridin-6-ilcarbonil)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R,4R)-4-fluoro-2-(metoxicarbonil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R,4S)-4-fluoro-2-(metoxicarbonil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R,4R)-4-fluoro-2-(hidroximetil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2R,4S)-4-fluoro-2-(hidroximetil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[(2S)-1-(5-metil-1,3,4-oxadiazol-2-il)pirrolidin-2-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(2-oxo-1,2-dihidropiridin-3-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de metilo

2-[4-(2-oxo-1,2-dihidropiridin-3-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(2-oxo-1,2-dihidropiridin-3-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de 2-fluoroetil

2-[4-(3-hidroxipiridin-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(2-metoxipiridin-3-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de 2-fluoroetilo

2-[4-(6-metoxi-4-metilpiridin-3-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(6-metoxi-5-metilpiridin-3-il)piperidin-1-il]-6-
 azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(2-aminopirimidin-4-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de
 etilo

2-[4-(4-aminopirimidin-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de
 etilo

2-[4-ciano-4-(piridin-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(2-metoxi-4-metilpiridin-3-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato
 de etilo

2-[4-(2-metoxi-5-metilpiridin-3-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-
 carboxilato de etilo

2-[4-(6-metoxipiridin-2-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de
 etilo

2-[4-(4-metil-2-oxo-1,2-dihidropiridin-3-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-
 carboxilato de etilo

2-[4-(4-metil-2-oxo-1,2-dihidropiridin-3-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-
 carboxilato de etilo

2-[4-(5-metil-2-oxo-1,2-dihidropiridin-3-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-
 carboxilato de etilo

2-[4-(2-oxo-1,2-dihidropiridin-4-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-
 carboxilato de etilo

2-(2-oxo-3,4'-bipiperidin-1'-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-(2-oxo-3,4'-bipiperidin-1'-il)-6-azaspiro[3.4]octano-6-carboxilato de metilo

2-(4-metil-2-oxo-3,4'-bipiperidin-1'-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-(5-metil-2-oxo-3,4'-bipiperidin-1'-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-(1-etil-2-oxo-3,4'-bipiperidin-1'-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[2-oxo-1-(propan-2-il)-3,4'-bipiperidin-1'-il]-6-azaspiro[3.4]octano-6-carboxilato
 de etilo

2-[4-(2-oxo-1,3-oxazinan-3-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato
 de etilo

2-[4-(2-oxotetrahidropirimidin-1(2H)-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-

carboxilato de etilo

2-[4-(5,5-dimetil-2-oxotetrahidropirimidin-1(2H)-il)piperidin-1-il]-6-

azaspiro[3.4]octano-6-carboxilato de etilo

2-(1,4'-bipiperidin-1'-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(morfolin-4-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(tiomorfolin-4-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-(3,3-difluoro-1,4'-bipiperidin-1'-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-(4,4-difluoro-1,4'-bipiperidin-1'-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo

(2R)-1'-[6-(etoxicarbonil)-6-azaspiro[3.4]oct-2-il]-1,4'-bipiperidina-2-carboxilato de metilo

2-[(2R)-2-(metilcarbamoil)-1,4'-bipiperidin-1'-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[(2R)-2-(dimetilcarbamoil)-1,4'-bipiperidin-1'-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[(2S)-2-(metilcarbamoil)-1,4'-bipiperidin-1'-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-(1-propanoil-2,4'-bipiperidin-1'-il)-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[1-(metilcarbamoil)-2,4'-bipiperidin-1'-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-[4-(2-oxoazepan-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo

2-{4-[2-(metoxicarbonil)azepan-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo

6. El compuesto de acuerdo con la reivindicación 1, que es 2-[4-(1-metil-1H-pirazol-5-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo.

7. El compuesto de acuerdo con la reivindicación 1, que es 2-[4-(1H-pirazol-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo.

8. El compuesto de acuerdo con la reivindicación 1, que es 2-{4-[(2R)-4,4-difluoro-2-(hidroximetil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo.

9. El compuesto de acuerdo con la reivindicación 1, que es 2-{4-[(2R)-4,4-difluoro-2-(1-hidroxietil)pirrolidin-1-il]piperidin-1-il}-6-azaspiro[3.4]octano-6-carboxilato de etilo.
10. El compuesto de acuerdo con la reivindicación 1, que es 2-[4-(2-oxopirrolidin-1-il)piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo.
11. El compuesto de acuerdo con la reivindicación 1, que es 2-[4-[(2S)-2-etil-5-oxopirrolidin-1-il]piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo.
12. El compuesto de acuerdo con la reivindicación 1, que es 2-[4-[(2R,4S)-4-fluoro-2-(metoxicarbonil)pirrolidin-1-il]piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo.
13. El compuesto de acuerdo con la reivindicación 1, que es 2-[4-[(2R,4R)-4-fluoro-2-(hidroximetil)pirrolidin-1-il]piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo.
14. El compuesto de acuerdo con la reivindicación 1, que es 2-[4-[(2R,4S)-4-fluoro-2-(hidroximetil)pirrolidin-1-il]piperidin-1-il]-6-azaspiro[3.4]octano-6-carboxilato de etilo.

PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITY

To:

see form PCT/ISA/220

PCT

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1)

Date of mailing
(day/month/year) see form PCT/ISA/210 (second sheet)

Applicant's or agent's file reference
see form PCT/ISA/220

FOR FURTHER ACTION
See paragraph 2 below

International application No.
PCT/GB2015/050331

International filing date (day/month/year)
06.02.2015

Priority date (day/month/year)
06.02.2014

International Patent Classification (IPC) or both national classification and IPC
INV. C07D401/14 C07D405/14 C07D413/14 C07D401/04 C07D409/14 C07D417/14 C07D471/04 C07D491/107
A61K31/454

Applicant
HEPTARES THERAPEUTICS LIMITED

1. This opinion contains indications relating to the following items:

- ☒ Box No. I Basis of the opinion
- ☒ Box No. II Priority
- ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step and industrial applicability; citations and explanations supporting such statement
- ☒ Box No. VI Certain documents cited
- ☒ Box No. VII Certain defects in the international application
- ☒ Box No. VIII Certain observations on the international application

2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

Name and mailing address of the ISA:



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0
Fax: +49 89 2399 - 4465

Date of completion of
this opinion

see form
PCT/ISA/210

Authorized Officer

Telephone No. +49 89 2399-0



**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.
PCT/GB2015/050331

Box No. I Basis of the opinion

1. With regard to the **language**, this opinion has been established on the basis of:
 - ☒ the international application in the language in which it was filed
 - ☐ a translation of the international application into , which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1 (b)).
2. ☐ This opinion has been established taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91 (Rule 43bis.1(a))
3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, this opinion has been established on the basis of a sequence listing filed or furnished:
 - a. (means)
 - ☐ on paper
 - ☐ in electronic form
 - b. (time)
 - ☐ in the international application as filed
 - ☐ together with the international application in electronic form
 - ☐ subsequently to this Authority for the purposes of search
4. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
5. Additional comments:

Box No. II Priority

1. ☒ The validity of the priority claim has not been considered because the International Searching Authority does not have in its possession a copy of the earlier application whose priority has been claimed or, where required, a translation of that earlier application. This opinion has nevertheless been established on the assumption that the relevant date (Rules 43bis.1 and 64.1) is the claimed priority date.
2. ☐ This opinion has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid (Rules 43bis.1 and 64.1). Thus for the purposes of this opinion, the international filing date indicated above is considered to be the relevant date.
3. Additional observations, if necessary:

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.
PCT/GB2015/050331

Box No. V Reasoned statement under Rule 43*bis*.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	<u>1-26</u>
	No: Claims	
Inventive step (IS)	Yes: Claims	<u>1-26</u>
	No: Claims	
Industrial applicability (IA)	Yes: Claims	<u>1-26</u>
	No: Claims	

2. Citations and explanations

see separate sheet

Box No. VI Certain documents cited

1. Certain published documents (Rules 43*bis*.1 and 70.10)

and / or

2. Non-written disclosures (Rules 43*bis*.1 and 70.9)

see form 210

Box No. VII Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

Reference is made to the following documents:

- D1 WO 2013/072705 A1 (HEPTARES THERAPEUTICS LTD.) 23 May 2013 (2013-05-23)
- D2 WO 2007/100670 A1 (VERTEX PHARMACEUTICALS INC.) 7 September 2007 (2007-09-07)
- D3 WO 2014/045031 A1 (HEPTARES THERAPEUTICS LTD.) 27 March 2014 (2014-03-27)

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

- 1 Reference is made to the following document:
 - D1 WO 2013/072705 A1 (HEPTARES THERAPEUTICS LTD.) 23 May 2013 (2013-05-23)
- 2 D1 is regarded as being the prior art closest to the subject-matter of claim 1, and discloses muscarinic M1 receptor agonists based on N-alkoxycarbonyl-piperidines which are substituted at the 4-position by a piperidin-1-yl moiety which is substituted at the 4-position by alkylaminocarbonyl.

The subject-matter of claim 1 therefore differs from this known formula in that the N-acylated piperidine is replaced by a 6-aza-spiro[4,3]octane moiety, and is therefore new (Article 33(2) PCT).

The problem to be solved by the present invention may be regarded as the provision of further muscarinic M1 receptor agonists.

The solution to this problem proposed in claim 1 of the present application is considered as involving an inventive step (Article 33(3) PCT) for the following reasons:

The presently claimed compounds cannot be considered to be structurally close to the compounds of D1. There is no information in D1 to suggest that further muscarinic M1 receptor could be made based on an N-acylated 6-aza-spiro[4,3]octane substituted at the 4-position by a piperidine moiety. D2

discloses further muscarinic receptor agonists based on spiro condensed piperidines, but these compounds are structurally less close than the compounds of D1.

- 3 Claims 2-19 are dependent on claim 1 whose subject-matter is considered as being new and inventive, as discussed above, and as such said dependent claims also meet the requirements of the PCT with respect to novelty and inventive step. Claim 21 drawn to pharmaceutical compositions containing compounds of claim 1, claim 22 drawn to compounds of claim 1 having pharmaceutical activity, claim 23 drawn to embodiments of the previous claims, and claims 24 to 26 drawn to compounds of claim 1 for use in therapy are also new and inventive by consequence.

Re Item VI

Certain documents cited

Application No Patent No	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
WO2014 045301	27.03.2014	18.09.2013	18.09.2012

WO-A-2014 045301 (D3) discloses muscarinic M1 receptor agonists based on N-alkoxycarbonyl-6-aza-spiro[3.4]octanes substituted at the 4-position by piperidin-1-yl. The piperidine group is substituted at the 4-position by aminocarbonyl, while in the presently claimed compounds, the piperidine is substituted at the 4-position by a heterocyclic group. If during the further examination procedure it is found that the presently claimed subject matter is not fully entitled to the claimed priority date, D3 may be taken into consideration for the evaluation of inventive step.

Re Item VII

Certain defects in the international application

In order to meet the requirements of Rule 5.1(a)(ii) PCT, documents D1 and D3 should be mentioned in the description and the relevant prior art disclosed therein should be briefly discussed.

Re Item VIII

Certain observations on the international application

Claim 23 makes reference to the description (Rule 6.2(a) PCT).

Claim 22 will be interpreted in the EP Phase as including compounds per se. If a medical use is intended, the correct format should be used.

Doctor

José Luis Salazar

Director de Nuevas Creaciones

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO

E.

S.

D.

Referencia: Expediente Núm. **NC2016/0001609**

Solicitud de Patente de Invención titulada: *“Compuestos aza bicíclicos como agonistas del receptor muscarínico M1”*

Solicitante: Heptares Therapeutics Limited

Asunto: **RESPUESTA OFICIO NO. 13643. EXAMEN DE FONDO**


JUAN PABLO CONCHA DELGADO, mayor de edad y vecino de Bogotá D.C., identificado tal como aparece al pie de mi firma, en mi carácter de apoderado de la sociedad en referencia, doy respuesta al auto emanado por ese Despacho dentro del término legal:


1. Respuesta a las Objeciones del Examinador

1.1 Claridad de la solicitud

El examinador afirma que: *"La reivindicación 1 carece de los requisitos de concisión y sustento descriptivo debido al uso de la expresión “opcionalmente sustituido” dentro de la definición de Q, ya que no se limita el número e identidad de dichos sustituyentes. De igual forma, los sustituyentes propuestos para Q no guardan similitud estructural entre sí que haga evidente su reemplazo, debido a que corresponde a anillos con diferente tamaño y que contienen diversos heteroátomos."*

Frente a lo anterior, de conformidad con el artículo 34 de la Decisión 486 y con el fin de atender a las objeciones presentadas por este Despacho en su oficio N° 13643, me permito presentar un nuevo capítulo reivindicatorio constituido por 14 reivindicaciones en donde se limita y se precisa mejor la invención.



Más específicamente, el resto  y el radical R^4 han sido limitados a compuestos específicos que corresponden a una generalización racional del alcance de la solicitud, presentan pleno sustento en la descripción y no comprende una ampliación de la materia tal cual fue presentada.

Adicionalmente, me permito agregar que la expresión "opcionalmente sustituido" ha sido modificada por "sustituido o no sustituido" la cual ahora dentro del contexto de la nueva reivindicación 1 limitada permite a la persona versada en la materia claramente deducir los sustituyentes que para el presente caso corresponden a "uno a seis átomos de flúor".

1.2 Novedad

El examinador reconoce la novedad de la presente solicitud. Por lo tanto, el requisito a sustentar es el nivel inventivo.


1.3 Nivel Inventivo

Sobre el requisito del nivel inventivo, el Examinador establece que una persona del nivel técnico medio, versada en la materia, incluiría un anillo no fusionado para formar el grupo espiro como lo enseña el documento **D2** (WO99/32489) "*Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions*" en el núcleo divulgado en el documento **D1** (WO2007/076070) "*Modulators of muscarinic receptors*" y llegaría de manera obvia a la solución que se propone en la presente solicitud. Particularmente, el Examinador considera que las reivindicaciones 1-13 carecen de nivel inventivo debido a las enseñanzas contenidas en D1 y D2.

El examinador afirma que el documento D1 se considera el estado de la técnica más cercano a la invención definida en la reivindicación 1 porque divulga un sistema policíclico que contempla un anillo espiro unido al sistema cíclico.

Además, menciona que la diferencia entre la presente invención y D1 consiste en que la anterioridad enseña un anillo fenil fusionado al espiro ciclopentil.

Sin embargo, el examinador afirma que D2 enseña agentes activos como moduladores muscarínicos sobre M1 y M4, donde A representa un grupo spiro que puede estar fusionado o no a un anillo cíclico:



por lo cual a partir de las enseñanzas de D2 es evidente la intercambiabilidad de estos anillos fusionados por un anillo simple.

Al respecto, mi representa está en total desacuerdo con la conclusión de su Despacho y enuncia que Colombia es el primer país que objeta el nivel inventivo de la presente invención. El requisito del nivel inventivo no fue objetado ni en la etapa del PCT ni en el trámite de la solicitud estadounidense US 15,591,605 equivalente a la presente invención. Adjunto copia de la opinión escrita de la autoridad de la búsqueda internacional de la solicitud internacional PCT/GB2015/050331, donde la oficina europea de patentes reconoció la novedad, nivel inventivo y aplicación industrial de las reivindicaciones 1 a 26. La copia de la notificación de otorgamiento de la solicitud estadounidense US 15,591,605 también se adjunta.

1.3.1 Argumentos adicionales en favor del nivel inventivo con respecto a D1 y D2:

El nivel inventivo de una solicitud se encuentra definido en el Artículo 18 de la Decisión 486 y se establece cuando “*si para una persona del oficio normalmente versada en la materia técnica correspondiente, esa invención no hubiese resultado obvia ni se hubiese derivado de manera evidente del estado de la técnica*”.


Contrario a lo que plantea el Examinador, los documentos del arte previo citados no afectan el nivel inventivo de la presente solicitud por cuanto no es posible derivar la presente invención a partir de las enseñanzas presentadas en los documentos D1 y D2, por lo siguiente:

a) Capítulo reivindicatorio modificado

Como lo mencioné anteriormente, se presenta un nuevo pliego reivindicatorio, el cual se limitó considerablemente.

b) Diferencias estructurales significativas entre los compuestos de la solicitud en estudio con respecto a D1 y D2 :

El documento D1 no puede afectar el nivel inventivo de la presente invención pues los compuestos de las reivindicaciones de la solicitud en estudio tienen estructuras muy diferentes a los compuestos revelados en D1.




El anillo fenil fusionado de D1 no hace parte de ninguno de los compuestos divulgados en la presente solicitud y corresponde a una diferencia estructural notable e influyente.



Contrario a lo afirmado por el examinador, la diferencia entre la presente invención y los compuestos de D1 no solamente es el anillo fenilo fusionado a la estructura sino también el resto Z_2-L-G (morado) como se muestra arriba, por ejemplo corresponde a estructuras totalmente distintas a las esperadas en la misma posición en los compuestos de la presente invención.

Por ejemplo, es completamente necesario para los compuestos en D1 que Z sea N, sin embargo los compuestos de la presente invención tienen un núcleo con una estructura única en donde dicha posición nunca es N.

Adicionalmente, los ejemplos divulgados y ensayados por D1 claramente evidencian que L y G corresponden a estructuras muy distintas a su equivalente estructural en los compuestos reclamados, tal como se puede ejemplificar a continuación:



Presente invención



Ejemplos 37 y 42 de D1


Además, al observar los ejemplos divulgados por D1 es posible observar que existen muchas más diferencias estructurales en los compuestos que demostraron actividad de D1.

Es importante hacer notar que el examinador ya mencionó una de las diferencias entre D1 y los presentes compuestos, correspondiente al anillo fenilo fusionado presente en D1, sin embargo afirma que partir del documento D2 es evidente la intercambiabilidad de estos anillos fusionados por un anillo simple.


Frente a esto, me permito aclarar que de ninguna manera es obvia a partir de D2 la eliminación del fenilo fusionado para llegar a los compuestos de la presente invención, ya que al observar los 509 compuestos divulgados por D1 cada uno tiene ese grupo fenilo.

Al estar la estructura de D1, señalada por el examinador, basada en el grupo fenilo, partiendo de D1 no habría sido obvio eliminar el anillo fenilo ya que esta es la única parte de la descripción y de los compuestos de la anterioridad **que permanece constante en todo momento.**

Adicional, a lo anterior el documento D2 divulga compuestos de fórmula:



Al observar la estructura de los compuestos de D2, en contraposición con los compuestos de la presente invención, podemos observar lo siguiente:



El grupo A correspondería, en los compuestos reclamados, a los que se encuentra en azul, para este

caso las reivindicaciones modificadas exclusivamente reclaman para el resto los grupos AAA a ACB, BAA a BCZ, CAA a CBZ, DAA a DBG y EAA a EAB, que de ninguna forma se parecen a la estructura formada con las opciones posibles para A en D2.

Por otra parte el examinador, parece no notar que la estructura formada por A en D2 correspondería a una estructura parecida al núcleo inamovible de los compuestos de la presente invención (mostrado dentro del círculo verde en la anterior figura), que claramente no está en la misma posición ni unida de la manera en que lo hacen los compuestos reclamados. "A" en la posición mostrada en D2 sí llevaría a algo más cercano a los compuestos mostrados en D1 pero de ninguna manera a los compuestos de la presente solicitud, reclamados en el capítulo reivindicatorio modificado adjunto.

Para poder llegar a la estructura del presente compuesto reivindicado a partir de la revelaciones de D1 y D2, una persona experta en la técnica se hubiera tenido que enfrentar con la tarea de realizar no una, sino múltiples modificaciones a las estructuras conocidas en el estado del arte sin siquiera esperar resultados exitosos en cuanto a la actividad, ya que ante dichas modificaciones estructurales sólo se podría esperar un cambio en la actividad demostrada por D1 y D2.

En base a todo lo anterior, es claro que el examinador está tomando partes aisladas de las estructuras encontradas en el estado del arte para intentar formar los compuestos de la presente solicitud. En esencia, el examinador ha reconstruido formulas estructurales por comparación utilizando el compuesto reclamado, es decir, reconstruye piezas de la estructura reivindicada en virtud de lo que se conoce en materia de patentes como “*hindsight*”.

En el presente caso, es claro que el examinador, efectúa un análisis de nivel inventivo equivocado e inadecuado, puesto que realizó un análisis *ex-post facto* (llamado *hindsight*, en inglés), al basar su análisis en la invención final, que como es obvio no la conocía el inventor cuando inició la investigación, y simplemente devolverse en el análisis de la invención y seleccionar y formar estructuras para llegar a compuestos que él considera como los más cercanos es inadmisibles.

En vista de esto, para lograr un correcto análisis sobre el nivel inventivo de una invención, el examinador, debe dar un paso atrás y ponerse en el momento en el que la invención no era conocida, y desde ahí, solo con sus conocimientos y lo que ya era conocido, evaluar si realmente hubiera sido obvio para un experto en la materia llegar a la invención en cuestión.

Por todo lo anterior, se concluye que los compuestos ahora reclamados en el nuevo capítulo reivindicatorio cumplen a cabalidad con los requisitos de patentabilidad establecidos en la Decisión 486 de la Comunidad Andina, y por lo tanto merecen el privilegio de patentabilidad solicitado.

2. Solicitudes concedidas en otros países para esta misma invención.

Como lo mencione arriba, pongo en conocimiento del Examinador que la oficina de patentes estadounidense expidió una notificación de otorgamiento de la solicitud US 15/591,605 (10 de mayo de 2017) equivalente a la presente solicitud colombiana.

El examinador podrá notar que el capítulo reivindicatorio que se presenta con este escrito es muy similar al contenido de las reivindicaciones otorgadas en la solicitud de patente US 15/591,605. Adjunto, copia de la notificación de otorgamiento y de las reivindicaciones concedidas en la solicitud de patente US 15/591,605.

Aún cuando entiendo que estas decisiones de ninguna manera obligan al Despacho para decidir de igual forma, considero que por tratarse de una pregunta fáctica la determinación de la existencia de nivel inventivo, las decisiones de otras oficinas de patentes constituyen un antecedente persuasivo en la materia.

En virtud de lo anterior, solicito que se acepten las razones expuestas en el presente documento y en consecuencia, se otorgue el privilegio de patente de invención para el invento que se tramita en este expediente.

Atentamente,


JUAN PABLO CONCHA
C.C. 80416654 de Bogotá
T.P. 80.677

Anexos:


- Capítulo reivindicatorio modificado conformado por 14 reivindicaciones
- Copia del Aviso de Concesión para US 15/591,605
- Reivindicaciones concedidas en US 15/591,605
- Pago de examen de patentabilidad
- Copia de la Opinión escrita de la autoridad de la búsqueda internacional para la solicitud PCT/GB2015/050331

ALLOWED CLAIMS


USSN 15/591,605 - 125345-00702

1-26. (Cancelled)


27. (Previously Presented) A compound of the formula:




or a salt thereof, wherein the moiety:




is selected from groups AAA to ACB, BAA to BCZ, CAA to CBZ, DAA to DBG and EAA to EAB:




AAA




AAB




AAC




AAD




AAE







AAF




AAG




AAH




AAI




AAM




AAQ




AAU




AAY




ABC




ABG




ABK




ABO




AAJ




AAN




AAR




AAV




AAZ




ABD




ABH




ABL




ABP




AAK




AAO




AAS




AAW




ABA




ABE




ABI




ABM




ABQ




AAL




AAP




AAT




AAX




ABB




ABF




ABJ




ABN




ABR




ABS




ABT




ABU




ABV



ABW



ABX




ABY




ABZ




ACA




ACB




ACD




ACE




BAA




BAB




BAC




BAD




BAE




BAF




BAG




BAH




BAI




BAJ




BAK




BAL




BAM




BAN




BAO




BAP




BAQ




BAR



BAS




BAT




BAU



BAV




BAW




BAX







BAY




BAZ




BBA




BBB




BBC




BBD




BBE




BBF




BBG




BBH




BBI




BBJ




BBK




BBL




BBM




BBN




BBO




BBP




BBQ




BBR




BBS




BBT




BBU




BBV




BBW




BBX




BBY




BBZ




BCA




BCB




BCD




BCE




BCF




BCG




BCH




BCI




BCJ




BCK




BCL




BCM




BCN




BCO




BCP




BCQ




BCR




BCS




BCT




BCU




BCV




BCW




BCX




BCY




BCZ




CAA




CAB




CAC




CAD




CAE



CAF




CAG






CAH


CAE




CAF




CAI




CAJ




CAK




CAL




CAM




CAN




CAO




CAP




CAQ




CAR




CAS




CAT




CAU




CAV




CAW




CAX




CAY




CAZ




CBA




CBB




CBC




CBD



CBE



CBF



CBG



CBH




CBI




CBJ







CBK




CBL




CBM




CBN




CBO




CBP




CBQ




CBR




CBS




CBT




CBU




CBV




CBW




CBX




CBY




CBZ




DAA




DAB




DAC




DAD




DAE




DAF




DAG




DAH




DAI




DAJ




DAK




DAL




DAM




DAN




DAO




DAP




DAQ




DAR




DAS




DAT




DAU




DAV




DAW




DAX




DAY




DAZ




DBA




DBB




DBC




DBD




DBE




DBF



DBG



EAA



EAB

R^3 is selected from hydrogen; fluorine; hydroxyl, methoxy and cyano; and

R^4 is a hydrogen or a C_{1-6} non-aromatic hydrocarbon group which is optionally substituted with one to six fluorine atoms.

28. (Previously presented) The compound according to claim 27 wherein R^4 is selected from hydrogen and methyl.
29. (Previously presented) The compound according to claim 27 wherein the salt is a pharmaceutically acceptable salt.

30. (Previously Presented) The compound according to claim 28 which is a pharmaceutically acceptable salt of a compound selected from the group consisting of:
- ethyl 2-[4-(1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
- ethyl 2-[4-(1H-pyrrol-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
- ethyl 2-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
- ethyl 2-[4-(1-ethyl-1H-pyrazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
- ethyl 2-[4-(2*H*-1,2,3-triazol-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
- ethyl 2-{4-[(2*S*)-1-propanoylpyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
- ethyl 2-{4-[1-(methylcarbamoyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
- ethyl 2-{4-[(2*S*)-1-(methoxycarbonyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
- ethyl 2-{4-[(2*R*)-4,4-difluoro-2-(methoxycarbonyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
- ethyl 2-{4-[(2*R*)-4,4-difluoro-2-(1-hydroxyethyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
- ethyl 2-{4-[(2*R*)-2-methyl-5-oxopyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
- ethyl 2-{4-[(2*R*)-2-ethyl-5-oxopyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
- ethyl 2-{4-[(2*S*)-2-methyl-5-oxopyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
- ethyl 2-{4-[(2*S*)-2-ethyl-5-oxopyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
- ethyl 2-[4-(2,2-dimethyl-5-oxopyrrolidin-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
- ethyl 2-{4-[2-(1,2-oxazol-3-yl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate

ethyl 2-{4-[(2*R*,4*S*)-4-fluoro-2-(methoxycarbonyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
ethyl 2-{4-[(2*R*,4*R*)-4-fluoro-2-(hydroxymethyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
ethyl 2-[4-cyano-4-(pyridin-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
ethyl 2-(2-oxo-3,4'-bipiperidin-1'-yl)-6-azaspiro[3.4]octane-6-carboxylate; and
ethyl 2-{4-[2-(methoxycarbonyl)azepan-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate.

31. (Previously presented) The compound according to claim 29 which is a pharmaceutically acceptable salt of a compound selected from the group consisting of:

Ethyl 2-[4-(1*H*-imidazol-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-[4-(4-chloro-1*H*-imidazol-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-{4-[4-(trifluoromethyl)-1*H*-imidazol-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-[4-(4-cyano-1*H*-imidazol-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-[4-(4,5-dichloro-1*H*-imidazol-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Methyl 2-[4-(1-methyl-1*H*-imidazol-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-[4-(1-methyl-1*H*-imidazol-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-{4-[1-(ethoxycarbonyl)-1*H*-imidazol-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;

Methyl 2-[4-(1,5-dimethyl-1*H*-imidazol-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-[4-(1,5-dimethyl-1*H*-imidazol-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Methyl 2-[4-(1,4-dimethyl-1H-imidazol-2-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(1,4-dimethyl-1H-imidazol-2-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 methyl 2-[4-(5-chloro-1-methyl-1H-imidazol-2-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(5-chloro-1-methyl-1H-imidazol-2-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Methyl 2-[4-(4,5-dichloro-1-methyl-1H-imidazol-2-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(4,5-dichloro-1-methyl-1H-imidazol-2-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(1H-pyrazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[4-(3-amino-1H-pyrazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Methyl 2-[4-(1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-
 6-carboxylate;
 Ethyl 2-[4-(1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[4-(1-methyl-1H-pyrazol-3-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[4-(1,3-oxazol-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Methyl 2-[4-(1,3-thiazol-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[4-(1,3-thiazol-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[4-(4H-1,2,4-triazol-3-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-

carboxylate;
 Ethyl 2-[4-(5-ethyl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(1,3,4-oxadiazol-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(3-methyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(1,2,4-thiadiazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(1H-tetrazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(1H-pyrrol-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(4-methyl-1H-pyrazol-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(1H-1,2,3-triazol-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(1H-1,2,4-triazol-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-hydroxy-4-(1H-imidazol-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(1H-imidazol-2-yl)-4-methoxypiperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-hydroxy-4-(1-methyl-1H-imidazol-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-methoxy-4-(1-methyl-1H-imidazol-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-methyl-4-(3-methyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Methyl 2-[4-(4-methyl-1*H*-pyrazol-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-[4-(1,2-oxazol-3-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-[4-(3-methyl-1*H*-pyrazol-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Methyl 2-[4-(3-methyl-1*H*-pyrazol-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Methyl 2-[4-(1-ethyl-1*H*-pyrazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-[4-(1-ethyl-1*H*-pyrazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Methyl 2-[4-(1-propyl-1*H*-pyrazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-[4-(1-propyl-1*H*-pyrazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-[4-(1,3-thiazol-4-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-{4-[1-(2-methoxyethyl)-1*H*-imidazol-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-{4-[1-(cyanomethyl)-1*H*-imidazol-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;

(2-{1-[6-(ethoxycarbonyl)-6-azaspiro[3.4]oct-2-yl]piperidin-4-yl}-1*H*-imidazol-1-yl)acetic acid;

Ethyl 2-(4-{1-[2-(methylamino)-2-oxoethyl]-1*H*-imidazol-2-yl}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;

Methyl 2-[4-(1,4-dimethyl-1*H*-pyrazol-3-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-[4-(1,4-dimethyl-1*H*-pyrazol-3-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Methyl 2-[4-(1,4-dimethyl-1*H*-pyrazol-5-yl)piperidin-1-yl]-6-

azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(1,4-dimethyl-1H-pyrazol-5-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(1-ethyl-4-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(4-ethyl-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(2H-1,2,3-triazol-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[4-(1H-tetrazol-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[4-(5-methyl-1H-tetrazol-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[4-(1-methyl-1H-tetrazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[4-(1-ethyl-1H-tetrazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[4-(2-ethyl-2H-tetrazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[4-(1-cyclopropyl-1H-tetrazol-5-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 (1,1-²H₂)Ethyl 2-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 (2,2,2-²H₃)Ethyl 2-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-
 6-carboxylate;
 (²H₅)Ethyl 2-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 (1,1-²H₂)Ethyl 2-[4-(1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 (2,2,2-²H₃)Ethyl 2-[4-(1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;

(²H₅)Ethyl 2-[4-(1-methyl-1*H*-pyrazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-[4-(pyrrolidin-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-[4-(1-formylpyrrolidin-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-[4-(1-acetylpyrrolidin-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-{4-[1-(trifluoroacetyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;

Methyl 2-[4-(1-propanoylpyrrolidin-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-[4-(1-propanoylpyrrolidin-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-{4-[(2*S*)-1-propanoylpyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-{4-[(2*S*)-1-(cyclopropylcarbonyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-{4-[(2*S*)-1-(cyclobutylcarbonyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;

Methyl 2-{4-[1-(methoxycarbonyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-{4-[1-(methoxycarbonyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-{4-[(2*S*)-1-(methoxycarbonyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-{4-[(2*R*)-1-(methoxycarbonyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-{4-[1-(ethoxycarbonyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;

Methyl 2-{4-[(2*S*)-1-(methylcarbamoyl)pyrrolidin-2-yl]piperidin-1-yl}-6-

azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[1-(methylcarbamoyl)pyrrolidin-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2S)-1-(methylcarbamoyl)pyrrolidin-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2R)-1-(methylcarbamoyl)pyrrolidin-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[1-(ethylcarbamoyl)pyrrolidin-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[1-(dimethylcarbamoyl)pyrrolidin-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2S)-1-(dimethylcarbamoyl)pyrrolidin-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(1-methylpyrrolidin-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-{4-[1-(*N*-methylglycyl)pyrrolidin-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[1-(methoxycarbamoyl)pyrrolidin-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2S)-1-(propan-2-ylcarbamoyl)pyrrolidin-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{(2S)-1-[(2,2,2-trifluoroethyl)carbamoyl]pyrrolidin-2-yl}piperidin-
 1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2S)-1-(azetidin-1-ylcarbonyl)pyrrolidin-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2S)-1-(morpholin-4-ylcarbonyl)pyrrolidin-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2S)-1-(cyclopropylcarbamoyl)pyrrolidin-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2S)-1-(cyclobutylcarbamoyl)pyrrolidin-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-(4-{(2*S*)-1-[(2-methoxyethyl)carbamoyl]pyrrolidin-2-yl}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-(pyrrolidin-1-ylcarbonyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-(methoxycarbamoyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{(2*S*)-1-[methoxy(methyl)carbamoyl]pyrrolidin-2-yl}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{(2*S*)-1-[(1-methylcyclobutyl)carbamoyl]pyrrolidin-2-yl}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{(2*S*)-1-[(3-methyloxetan-3-yl)carbamoyl]pyrrolidin-2-yl}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{(2*S*)-1-[(3,3-difluoropyrrolidin-1-yl)carbonyl]pyrrolidin-2-yl}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{(2*S*)-1-[(3,3-difluorocyclobutyl)carbamoyl]pyrrolidin-2-yl}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{(2*S*)-1-[(3,3-difluoroazetidin-1-yl)carbonyl]pyrrolidin-2-yl}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Methyl 2-(4-{(2*S*)-1-[(2,2,2-trifluoroethyl)carbamoyl]pyrrolidin-2-yl}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Methyl 2-(4-{(2*S*)-1-[(3,3-difluoroazetidin-1-yl)carbonyl]pyrrolidin-2-yl}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{(2*S*)-1-[ethyl(propan-2-yl)carbamoyl]pyrrolidin-2-yl}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{(2*S*)-1-[(cyclobutyloxy)carbonyl]pyrrolidin-2-yl}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{(2*S*)-1-[(2-fluoroethyl)carbamoyl]pyrrolidin-2-yl}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{(2*S*)-1-[(2,2-difluoroethyl)carbamoyl]pyrrolidin-2-yl}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-(methoxyacetyl)pyrrolidin-2-yl]piperidin-1-yl}-6-

azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{{(2*S*)-1-[(2-fluoroethoxy)carbonyl]pyrrolidin-2-yl}}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{{(2*S*)-1-[(2,2,2-trifluoroethoxy)carbonyl]pyrrolidin-2-yl}}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{{(2*S*)-1-[(methylsulfanyl)carbonyl]pyrrolidin-2-yl}}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{{(2*S*)-1-[(2-methoxyethoxy)carbonyl]pyrrolidin-2-yl}}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-{[2-(dimethylamino)ethoxy]carbonyl}pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-(hydroxyacetyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-(3,3,3-trifluoropropanoyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 ethyl 2-(4-{{(2*S*)-1-[(pyridin-2-ylmethyl)carbamoyl]pyrrolidin-2-yl}}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{{(2*S*)-1-[methyl(2,2,2-trifluoroethyl)carbamoyl]pyrrolidin-2-yl}}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-(oxetan-3-ylcarbamoyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{{(2*S*)-1-[methyl(oxetan-3-yl)carbamoyl]pyrrolidin-2-yl}}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-propanethiopyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*,4*S*)-4-fluoro-1-propanoylpyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-4,4-difluoro-1-propanoylpyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-ethylpyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-(4-{(2*S*)-1-[3-(pyridin-2-yl)propanoyl]pyrrolidin-2-yl}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{(2*S*)-1-[methyl(pyridin-2-ylmethyl)carbamoyl]pyrrolidin-2-yl}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{(2*S*)-1-[(pyridin-2-ylmethoxy)carbonyl]pyrrolidin-2-yl}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-{*N*-[(benzyloxy)carbonyl]-β-alanyl}pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-(β-alanyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-{[2-(methylamino)ethoxy]carbonyl}pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-(2-fluoroethyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-(2,2,2-trifluoroethyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-(3,3,3-trifluoropropyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-(2-methoxyethyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-(2-methoxy-2-oxoethyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{(2*S*)-1-[2-(dimethylamino)-2-oxoethyl]pyrrolidin-2-yl}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-benzylpyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-(methylcarbamothioyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[2-(methylcarbamoyl)-2,3-dihydro-1*H*-isoindol-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-phenylpyrrolidin-2-yl]piperidin-1-yl}-6-

azaspiro[3.4]octane-6-carboxylate;
 Methyl 2-{4-[(2S)-1-(pyridin-2-yl)pyrrolidin-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2S)-1-(pyridin-2-yl)pyrrolidin-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2S)-1-(pyridin-4-yl)pyrrolidin-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2S)-1-(pyrimidin-2-yl)pyrrolidin-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2S)-1-(1,3-thiazol-2-yl)pyrrolidin-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2S)-1-(1,3,4-thiadiazol-2-yl)pyrrolidin-2-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2R)-2-(methoxycarbonyl)pyrrolidin-1-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2S)-2-(methylcarbamoyl)pyrrolidin-1-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 1-{1-[6-(ethoxycarbonyl)-6-azaspiro[3.4]oct-2-yl]piperidin-4-yl}-4,4-difluoro-
 D-proline;
 Ethyl 2-{4-[(2R)-4,4-difluoro-2-(methoxycarbonyl)pyrrolidin-1-yl]piperidin-1-
 yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2R)-4,4-difluoro-2-(methylcarbamoyl)pyrrolidin-1-yl]piperidin-1-
 yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2R)-2-(dimethylcarbamoyl)-4,4-difluoropyrrolidin-1-yl]piperidin-
 1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2R)-2-carbamoyl-4,4-difluoropyrrolidin-1-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2R)-4,4-difluoro-2-(methoxycarbamoyl)pyrrolidin-1-yl]piperidin-
 1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-{(2R)-4,4-difluoro-2-[methoxy(methyl)carbamoyl]pyrrolidin-1-
 yl}piperidin-1-yl)-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-{4-[(2*S*)-4,4-difluoro-2-(methylcarbamoyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-2-(dimethylcarbamoyl)-4,4-difluoropyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*R*)-2-(methoxycarbonyl)-2-methylpyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(6-oxo-7-oxa-1-azaspiro[4.4]non-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(4*S*)-4-(methoxycarbonyl)-1,3-thiazolidin-3-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(3*R*)-3-fluoropyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(3*S*)-3-fluoropyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(3,3-difluoropyrrolidin-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-2-(trifluoromethyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*R*)-2-(fluoromethyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*R*)-2-(difluoromethyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*R*)-2-(trifluoromethyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(3-azabicyclo[3.1.0]hex-3-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-4,4-difluoro-2-methylpyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*R*)-4,4-difluoro-2-(hydroxymethyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*R*)-4,4-difluoro-2-(methoxymethyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;

yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2R)-4,4-difluoro-2-(1-hydroxyethyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2R)-4,4-difluoro-2-(2-hydroxypropan-2-yl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(2-oxopyrrolidin-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(2,5-dioxopyrrolidin-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2R)-2-methyl-5-oxopyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2R)-2-ethyl-5-oxopyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2S)-2-methyl-5-oxopyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2S)-2-ethyl-5-oxopyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(2,2-dimethyl-5-oxopyrrolidin-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(4R)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(4R)-4-ethyl-2-oxo-1,3-oxazolidin-3-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(4R)-2-oxo-4-(propan-2-yl)-1,3-oxazolidin-3-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(4S)-4-ethyl-2-oxo-1,3-oxazolidin-3-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(4S)-2-oxo-4-(propan-2-yl)-1,3-oxazolidin-3-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;

Ethyl 2-[4-(2-oxoimidazolidin-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(3-methyl-2-oxoimidazolidin-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[2-(1*H*-pyrazol-5-yl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[2-(1,2-oxazol-3-yl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[2-(1*H*-tetrazol-5-yl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[2-(2-methyl-2*H*-tetrazol-5-yl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[2-(1-methyl-1*H*-tetrazol-5-yl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*R*)-2-(thiophen-2-yl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*R*)-2-(1,3-thiazol-2-yl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-(5,7-dihydro-6*H*-pyrrolo[3,4-*b*]pyridin-6-ylcarbonyl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*R*,4*R*)-4-fluoro-2-(methoxycarbonyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*R*,4*S*)-4-fluoro-2-(methoxycarbonyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*R*,4*R*)-4-fluoro-2-(hydroxymethyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*R*,4*S*)-4-fluoro-2-(hydroxymethyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-{4-[(2*S*)-1-(5-methyl-1,3,4-oxadiazol-2-yl)pyrrolidin-2-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate;

Methyl 2-[4-(2-oxo-1,2-dihydropyridin-3-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(2-oxo-1,2-dihydropyridin-3-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 2-Fluoroethyl 2-[4-(2-oxo-1,2-dihydropyridin-3-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(3-hydroxypyridin-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 2-Fluoroethyl 2-[4-(2-methoxypyridin-3-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(6-methoxy-4-methylpyridin-3-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(6-methoxy-5-methylpyridin-3-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 ethyl 2-[4-(2-aminopyrimidin-4-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[4-(4-aminopyrimidin-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 ethyl 2-[4-cyano-4-(pyridin-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[4-(2-methoxy-4-methylpyridin-3-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(2-methoxy-5-methylpyridin-3-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(6-methoxypyridin-2-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[4-(4-methyl-2-oxo-1,2-dihydropyridin-3-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(4-methyl-2-oxo-1,2-dihydropyridin-3-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(5-methyl-2-oxo-1,2-dihydropyridin-3-yl)piperidin-1-yl]-6-

azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(2-oxo-1,2-dihydropyridin-4-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(2-oxo-3,4'-bipiperidin-1'-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Methyl 2-(2-oxo-3,4'-bipiperidin-1'-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(4-methyl-2-oxo-3,4'-bipiperidin-1'-yl)-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-(5-methyl-2-oxo-3,4'-bipiperidin-1'-yl)-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-(1-ethyl-2-oxo-3,4'-bipiperidin-1'-yl)-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[2-oxo-1-(propan-2-yl)-3,4'-bipiperidin-1'-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[4-(2-oxo-1,3-oxazinan-3-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[4-(2-oxotetrahydropyrimidin-1(2*H*)-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(5,5-dimethyl-2-oxotetrahydropyrimidin-1(2*H*)-yl)piperidin-1-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(1,4'-bipiperidin-1'-yl)-6-azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[4-(morpholin-4-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[4-(thiomorpholin-4-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-(3,3-difluoro-1,4'-bipiperidin-1'-yl)-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-(4,4-difluoro-1,4'-bipiperidin-1'-yl)-6-azaspiro[3.4]octane-6-
 carboxylate;
 Methyl (2*R*)-1'-[6-(ethoxycarbonyl)-6-azaspiro[3.4]oct-2-yl]-1,4'-bipiperidine-
 2-carboxylate;
 Ethyl 2-[(2*R*)-2-(methylcarbamoyl)-1,4'-bipiperidin-1'-yl]-6-

azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[(2*R*)-2-(dimethylcarbamoyl)-1,4'-bipiperidin-1'-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-[(2*S*)-2-(methylcarbamoyl)-1,4'-bipiperidin-1'-yl]-6-
 azaspiro[3.4]octane-6-carboxylate;
 Ethyl 2-(1-propanoyl-2,4'-bipiperidin-1'-yl)-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[1-(methylcarbamoyl)-2,4'-bipiperidin-1'-yl]-6-azaspiro[3.4]octane-6-
 carboxylate;
 Ethyl 2-[4-(2-oxoazepan-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-
 carboxylate; or
 Ethyl 2-{4-[2-(methoxycarbonyl)azepan-1-yl]piperidin-1-yl}-6-
 azaspiro[3.4]octane-6-carboxylate.

32. (Previously Presented) A pharmaceutical composition comprising a compound as defined in claim 27 and a pharmaceutically acceptable excipient.
33. (Previously Presented) The compound according to claim 27 wherein the compound has a muscarinic M₁ receptor and/or M₄ receptor agonist activity.
34. (Previously Presented) A method of treating a cognitive disorder in a subject, comprising administering an effective amount of the compound of claim 27 to the subject in need thereof.
35. (Previously Presented) A method of treating Alzheimer's Disease or dementia with Lewy bodies in a subject, comprising administering an effective amount of the compound of claim 27 to the subject in need thereof.
36. (Previously presented) The compound according to claim 27 which is ethyl 2-[4-(1-methyl-1*H*-pyrazol-5-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate.

37. (Previously presented) The compound according to claim 27 which is ethyl 2-[4-(1H-pyrazol-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate.
38. (Previously presented) The compound according to claim 27 which is ethyl 2-{4-[(2R)-4,4-difluoro-2-(hydroxymethyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate.
39. (Previously presented) The compound according to claim 27 which is ethyl 2-{4-[(2R)-4,4-difluoro-2-(1-hydroxyethyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate.
40. (Previously presented) The compound according to claim 27 which is ethyl 2-[4-(2-oxopyrrolidin-1-yl)piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylate.
41. (Previously presented) The compound according to claim 27 which is ethyl 2-{4-[(2S)-2-ethyl-5-oxopyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate.
42. (Previously presented) The compound according to claim 27 which is ethyl 2-{4-[(2R,4S)-4-fluoro-2-(methoxycarbonyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate.
43. (Previously presented) The compound according to claim 27 which is ethyl 2-{4-[(2R,4R)-4-fluoro-2-(hydroxymethyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate.
44. (Previously presented) The compound according to claim 27 which is ethyl 2-{4-[(2R,4S)-4-fluoro-2-(hydroxymethyl)pyrrolidin-1-yl]piperidin-1-yl}-6-azaspiro[3.4]octane-6-carboxylate.